A new trade agreement between the European Union and the United States institutes a 15% tariff on pharmaceutical imports, marking a significant change from previous zero tariffs. While characterized as a ceiling to prevent further increases, the tariff step has raised concerns within the pharmaceutical sector regarding market access and pricing. The deal, agreed upon by EU Commission President Ursula von der Leyen and US President Donald Trump, reflects ongoing trade negotiations affecting biopharma commerce.